Technical Analysis for SCLP - Scancell Holdings Plc

Grade Last Price % Change Price Change
F 10.25 0.00% 0.00
SCLP closed unchanged on Thursday, March 28, 2024, on 74 percent of normal volume. Note that the stock is in oversold territory based on its Slow Stochastic indicator (14, 3, 3) -- so don't be surprised if it goes sideways or bounces.
0 Watchers
Watchlist Portfolio

Trend Table & Recent EOD Trading Signals

ADX Long Term Intermediate Term Short Term
Weak or Absent Down Down Down

Date Alert Name Type % Chg
Stochastic Buy Signal Bullish 0.00%
Doji - Bullish? Reversal 0.00%
Oversold Stochastic Weakness 0.00%
20 DMA Resistance Bearish 0.00%
Non-ADX 1,2,3,4 Bearish Bearish Swing Setup 0.00%
NR7 Range Contraction 0.00%
Inside Day Range Contraction 0.00%
Oversold Stochastic Weakness 0.00%
20 DMA Resistance Bearish 0.00%
50 DMA Resistance Bearish 0.00%

   Recent Intraday Alerts

Alert Time
Non-ADX 1,2,3,4 Bearish Retracement Entry about 11 hours ago
Fell Below Previous Day's Low about 11 hours ago
Down 2% about 11 hours ago
Down 1% about 11 hours ago
Outside Day about 11 hours ago

Get a Trading Sidekick!

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.

Profile

Scancell Holdings Plc Description

Scancell Holdings plc is a biopharmaceutical company focused on the cancer therapeutics market. The Company's principal activity consists of the discovery and development of monoclonal antibodies and vaccines for the treatment of cancer. The Company is developing a pipeline of immunotherapies for the treatment of cancer based on its ImmunoBody and Moditope platforms. The Company's products include SCIB1, SCIB2 and Modi-1. The Company's first cancer vaccine, SCIB1, is being developed for the treatment of melanoma and is in Phase I/II clinical trials. SCIB2 contains multiple T cell epitopes derived from the lung cancer associated antigen NY-ESO-1. It is developed to the point at which the product is defined and ready for further preclinical development as an immunotherapy for any tumor that expresses the NY-ESO-1 antigen. The Company's first Moditope development candidate is Modi-1. Modi-1 consists of two citrullinated vimentin peptides and one citrullinated enolase peptide.


Classification

Sector: Healthcare
Industry: Biotechnology
Keywords: Biotechnology Pharmaceutical Medicine Cancer Pipe Branches Of Biology Medical Specialties Clinic Biopharmaceutical Therapy Clinical Trial Monoclonal Antibodies Antibodies Vaccine Antibody Immunology Tumor Immune System Therapies Lung Cancer Treatment Of Cancer Immunotherapies Melanoma Immunotherapy Cancer Therapeutics Monoclonal Antibody Treatment Of Melanoma

Is SCLP a Buy, Sell or Hold?

Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength

Indicators

Indicator Value
52 Week High 21.0
52 Week Low 7.588
Average Volume 321,571
200-Day Moving Average 11.74
50-Day Moving Average 10.89
20-Day Moving Average 10.48
10-Day Moving Average 10.33
Average True Range 0.62
RSI (14) 39.76
ADX 14.41
+DI 18.78
-DI 12.47
Chandelier Exit (Long, 3 ATRs) 10.15
Chandelier Exit (Short, 3 ATRs) 11.85
Upper Bollinger Bands 11.09
Lower Bollinger Band 9.87
Percent B (%b) 0.31
BandWidth 11.68
MACD Line -0.19
MACD Signal Line -0.19
MACD Histogram -0.0018
Fundamentals Value
Market Cap 95.1 Million
Num Shares 928 Million
EPS -0.01
Price-to-Earnings (P/E) Ratio -1025.00
Price-to-Sales 19.89
Price-to-Book 8.89
PEG Ratio 0.00
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 10.91
Resistance 3 (R3) 10.90 10.67 10.80
Resistance 2 (R2) 10.67 10.50 10.68 10.76
Resistance 1 (R1) 10.46 10.40 10.47 10.47 10.73
Pivot Point 10.23 10.23 10.24 10.24 10.23
Support 1 (S1) 10.02 10.06 10.03 10.03 9.77
Support 2 (S2) 9.79 9.96 9.80 9.74
Support 3 (S3) 9.58 9.79 9.70
Support 4 (S4) 9.59